Pharma Matters Q&A: AustinPx, Talking Next-Gen Amorphous Dispersion Technology

Dave Miller, Chief Scientific Officer of AustinPx, discusses in a recent Q&A why our innovative KinetiSol Technology will revolutionize amorphous solid dispersions (ASDs) for poorly soluble APIs. Unlike traditional spray drying, KinetiSol uses a solvent-free process, enhancing stability and bioavailability by preventing phase separation and directly dissolving drugs in polymers.

Miller explains how KinetiSol supports sustainable manufacturing by reducing solvent waste and offering economic benefits. The technology also accommodates thermally sensitive APIs and high melting point compounds, broadening the formulation toolbox. This versatile solution streamlines development timelines and ensures consistent quality from lab-scale to commercial production, making it a game-changer in the pharmaceutical industry.